Drug Trial Radar · NCT07229820
Efficacy and Safety of ZSP1273 in Adolecent 12-17 Years Old With Influenza A
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
157
Actual
Start
Nov 8, 2025
Primary completion
Dec 22, 2025
Study completion Jan 25, 2026
Sponsor
- Lead sponsor
- Guangdong Raynovent Biotech Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted in China. This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of ZSP1273 in the treatment of Acute Uncomplicated influenza A in adolescents.
Conditions
- Influenza A
Interventions
ZSP1273Drug
Oral
PlaceboDrug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Alleviation of SymptomsTime frame: DAY1~DAY15
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ruijin Hospital
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.